Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.24
-0.01 (-4.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.8M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$59M
P/E
N/A
•EV/EBITDA
17.4x
↑ROE
-32.5%
↓Gross Margin
28.1%
↓Debt/Equity
0.63
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.2%
FCF CAGR
—
FCF margin
15.9%
FCF / Net income
-0.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $51.4M · net income $-18.0M · FCF $8.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $51.4M | $51.4M | $36.0M | $34.8M | $35.4M |
| Net Income | $-18.0M | $-18.0M | $-22.4M | $4.4M | $10.9M |
| EBITDA | $5.1M | $5.1M | $-2.0M | $16.8M | $15.2M |
| EPS | -0.07 | -0.07 | -0.08 | 0.03 | 0.08 |
| Gross Margin | 28.1% | 28.1% | 24.9% | 34.6% | 65.2% |
| Operating Margin | -13.5% | -13.5% | -31.1% | -22.5% | 26.2% |
| Net Margin | -35.0% | -35.0% | -62.3% | 12.6% | 30.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.63 | 0.63 | 0.54 | 0.42 | 0.53 |
| Current Ratio | 0.62 | 0.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $8.1M | $8.1M | $1.8M | $1.7M | $-3.1M |
| Returns | |||||
| ROE | -32.5% | -32.5% | -30.6% | 4.8% | 15.2% |
| Valuation | |||||
| P/E | — | — | — | 9.83 | 3.44 |
| EV/EBITDA | 17.38 | 17.38 | — | 4.68 | 4.65 |
| P/B | 1.07 | 1.07 | 0.56 | 0.52 | 0.53 |
| Growth & Yield | |||||
| Revenue Growth | 42.7% | 42.7% | 3.4% | -1.7% | — |
| EPS Growth | 12.5% | 12.5% | -366.7% | -62.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+100.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.08 → -0.07
Residual
+100.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.